See more : The Very Good Food Company Inc. (VERY.V) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Land Business Co.,Ltd. (8944.T) Income Statement Analysis – Financial Results
- Fidelity Asian Values PLC (FAS.L) Income Statement Analysis – Financial Results
- Yangmei Chemical Co.,Ltd (600691.SS) Income Statement Analysis – Financial Results
- Bingo Group Holdings Limited (8220.HK) Income Statement Analysis – Financial Results
- Corner Growth Acquisition Corp. (COOL) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MNMD)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.16M | 3.22M | 2.62M | 0.00 | 6.68K | 6.68K | 5.50K | 0.00 | 0.00 |
| Gross Profit | -3.16M | -3.22M | -2.62M | 0.00 | -6.68K | -6.68K | -5.50K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 48.96M | 36.17M | 34.79M | 18.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 461.50K | 855.26K | 1.23M | 111.25K | 94.55K |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 468.18K | 861.94K | 1.24M | 111.25K | 94.55K |
| Interest Income | 4.66M | 1.50M | 0.00 | 0.00 | 0.00 | 4.00K | 8.40K | 1.20K | 1.90K |
| Interest Expense | 0.00 | 1.50M | 359.00K | 164.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.16M | 3.22M | 2.62M | 206.30K | 6.68K | 6.68K | 5.50K | 0.00 | 0.39 |
| EBITDA | -92.57M | -53.57M | -91.22M | -33.77M | -1.11M | -851.26K | -1.51M | -111.25K | -92.66K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -468.18K | -861.94K | -1.24M | -111.25K | -94.55K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | -647.63K | 4.00K | 8.40K | -68.65K | 1.89K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -9.54M | -1.16M | 164.00K | -3.69 | -1.91 | -1.70 | 0.00 | -0.39 |
| Net Income | -95.73M | -47.26M | -93.04M | -34.10M | -1.12M | -857.94K | -1.23M | -179.90K | -92.66K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| EPS Diluted | -2.44 | -1.53 | -3.40 | -1.92 | -2.94 | -2.74 | -4.85 | -2.24 | -1.17 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 379.41K | 312.55K | 252.82K | 80.42K | 79.00K |
MindMed Announces Business Update and Anticipated Milestones for 2024
NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today provided a corporate update and outlook for 2024. “Our strong progress...
Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this year
A financial backer of an effort to legalize the drug MDMA for therapeutic use sees the potential for “exponential growth” should it win approval from the U.S. Food and Drug Administration, possibly over this summer.
What Makes Mind Medicine (MindMed) Inc. (MNMD) a New Buy Stock
Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MindMed Advances Treatment for Generalized Anxiety Disorder
NEW YORK, NY, December 18, 2023 – Biopharmaceutical company, Mind Medicine (Nasdaq: MNMD) has announced positive results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and...
Mind Medicine's MM-120 shows promise in Phase 2b trial for Generalized Anxiety Disorder
Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) has announced encouraging results from its Phase 2b clinical trial of MM-120 in treating Generalized Anxiety Disorder (GAD). MM-120, a single-dose lysergide d-tartrate, demonstrated statistically significant and clinically meaningful improvements over placebo at Week 4,...
MindMed announces positive results in trial of LSD as a treatment for generalized anxiety disorder
Mind Medicine Inc. MNMD, +3.53% said Thursday a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores by week four compared to placebo. The trial of...
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial...
Mind Medicine (MindMed) Inc. (MNMD) Q3 2023 Earnings Call Transcript
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Rob Barrow - Chief Executive Officer Schond Greenway - Chief Financial Officer Dr. Dan Karlin - Chief Medical Officer Dr. Francois...
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed today reported its financial results for the quarter ended September 30, 2023.
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business Update
NEW YORK--(BUSINESS WIRE)---- $MNMD--MindMed plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET.
Source: https://incomestatements.info
Category: Stock Reports